Cluenex
Log inStart free
All stocks · Healthcare · Health Care Supplies

Envista NVST

Envista scores average on business quality (4.7 of 10). Here is why, in plain words, and what our sealed record shows.

Last price$23.00Oct 9, 2026
Business qualityAverage
Next earningsOct 27, 2026, after the close
Insiders, 90 daysQuiet

Why it matters

  1. What Envista does

    Envista Holdings manufactures dental implants, orthodontics, and equipment, selling directly to dental professionals and clinics globally. Leaner operations and improving demand are positioning the company for multi-year growth.

  2. What it does best

    Envista delivers a gross margin of 55.9%, outperforming peer TFX at 53.8%. This edge stems from proprietary dental implant systems that dentists rely on daily.

  3. The main risk

    Weak profitability limits earnings power, leaving net margin at just 3.3% on $2.9B in revenue. Any volume drop quickly compresses already thin earnings.

Quality, check by check

Scored against its own industry, from company filings.

ProfitabilityWeak

Operating margin rests at 10.6% alongside an FCF margin of 8.7%. Scale brings modest margin expansion.

MoatFair

Clinicians form its primary moat through product familiarity, sitting in the 38th percentile for sector gross margin.

GrowthSlow

Revenue grew 8.3% to $2.9B, marking an acceleration from prior flat multi-year trends visible in annual history.

Financial healthFair

Debt-to-equity sits at 0.5 with interest coverage at 8.6x, while free cash flow reached $249M. The balance sheet is holding steady.

Insiders

Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.

No open market buys or unplanned sales by executives or directors.

Our sealed record on NVST

Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.

The first sealed verdicts appear here on Oct 11, 2026.

Questions

Is NVST a good business?

Envista scores average on the Cluenex quality check (4.7 of 10), measured against its own industry. Profitability is weak, moat fair, growth slow and financial health fair.

Are insiders buying NVST?

In the last 90 days of SEC Form 4 filings: No open market buys or unplanned sales by executives or directors.

When does NVST report earnings?

Oct 27, 2026, after the close.

For members

See NVST today

  • Today's verdict on NVST, and why
  • Fair value with cautious, base and optimistic cases
  • The exact price that would change the verdict
  • Which stocks each signal names, the night it fires
Open in Cluenex Free to start. First month of Core free.

Cite this page: Cluenex, “Envista (NVST)”, https://cluenex.com/stocks/nvst/, data as of Oct 10, 2026.